Potential therapeutic options to prevent delayed cerebral ischemia ought to concentrate on augmenting the capacity of the intrathecal CD163-haptoglobin–hemoglobin scavenging system and strategies to encourage hemoglobin efflux from the brain. This evidence concerns the gene CD163 and brain ischemia.